Flawed from the start: COVID-19 vaccines are doomed to fail

01/28/2022 / By Kevin Hughes

The Wuhan coronavirus (COVID-19) vaccines made by Pfizer, AstraZeneca and Moderna do not prevent the SARS-CoV-2 virus from spreading.

This was proven by vaccine clinical trials and supported by what’s happening in the real world. The reality is, nothing has changed since the jabs were introduced. The vaccine makers have also designed a series of clinical trials that were bound to be a complete flop.

In a New York Times opinion article published September 22, 2020, Dr. Peter Doshi of the University of Maryland School of Pharmacy and Scripps Research Translational Institute Director Eric Topol discussed the flaws in the clinical trials conducted by Pfizer, AstraZeneca and Moderna. (Related: Everywhere you look, COVID “vaccines” are failing.)

The most glaring flaw was that the trials didn’t answer the question of whether the vaccines are able to protect people and prevent serious complications.

“If you were to approve a coronavirus vaccine, would you approve one that you knew protected people only from the most mild form of COVID-19, or one that would prevent its serious complications? The answer is obvious. You would want [the vaccine] to protect against the worst cases,” the article said.

“But that’s not how the companies testing three of the leading coronavirus vaccine candidates, Moderna, Pfizer and AstraZeneca, whose U.S. trial is on hold, are approaching the problem.”

COVID vaccines only effective at preventing “mild cases of COVID”

The article noted that, according to the protocols for the studies released in September 2020, “a vaccine could meet the companies’ benchmark for success if it lowered the risk of mild COVID-19, but was never shown to reduce moderate or severe forms of the disease, or the risk of hospitalization, admissions to the intensive care unit or death.”

“To say a vaccine works should mean that most people no longer run the risk of getting seriously sick. That’s not what these trials will determine,” the article stated.

This could only mean that the clinical trials were designed to display effectiveness in preventing “mild cases of COVID” but not the moderate or severe cases of the disease. It further showed that the vaccine clinical trials were completely useless and irrelevant and were done in a misleading and deceptive way.

The Moderna and AstraZeneca studies involved about 30,000 participants each while Pfizer had 44,000. Half the participants got two doses of vaccines separated by three or four weeks while the other half received saltwater placebo shots. The final determination of efficacy for the vaccines took place after 150 to 160 participants developed COVID-19.

However, the Moderna and Pfizer trials considered a cough plus a positive lab test to be a mild case of COVID-19. This qualification eventually muddied the test results. AstraZeneca, on the other hand, was stricter; but it still counted mild symptoms like a cough plus fever as a COVID-19 case.

Studies have shown that up to 90 percent of COVID-19 cases are false positives because the PCR test is too sensitive and registers “positive for COVID” when it shouldn’t. This means that the vaccine clinical trials’ process of determining the efficacy of the vaccines “after 150 to 160 people developed COVID-19” was utterly deceptive, useless and ridiculous. A positive PCR test is too unreliable and meaningless.

Pfizer, Moderna to begin omicron clinical trials

Meanwhile, both Pfizer and Moderna recently announced that they have begun clinical trials testing omicron-specific formulations of their mRNA COVID-19 vaccines.

Data from the trials are expected to emerge in the first half of 2022, but some experts hint that end of the year may be too late for omicron vaccines as the world could be dealing with new variants by then.

Pfizer was the first to announce the start of large clinical trials testing an omicron-specific mRNA vaccine. The plan is to enlist 1,420 participants dispersed across three groups.

The largest group, which has 615 subjects, will examine the safety and immunogenicity of the omicron-specific vaccine in those who got two doses of the standard Pfizer COVID-19 vaccine. A second group of 600 subjects with three doses of the standard mRNA vaccine will either receive a fourth dose of the omicron-specific formulation or the original formulation. The trials will also check for safety and immune responses in the groups.

Meanwhile, a third smaller group of around 200 unvaccinated subjects will be enrolled to test a complete three-dose protocol of the omicron-specific vaccine.